Novartis discontinues hydroxychloroquine clinical trial based on slow enrollment, remains committed to pandemic research efforts
Study discontinued due to feasibility of recruitment; no safety issues have been reported or efficacy conclusions made
- Novartis remains committed to ongoing research and development for COVID-19
- Supply of hydroxychloroquine (HCQ) from Novartis will continue for clinical trials and upon government requests worldwide
# # #
Novartis Media Relations E-mail:?media.relations@novartis.com